scholarly journals The Bioengineered Combo Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Coronary Stent in Patients with Chronic Total Occlusion Evaluated by Clinical Outcome and Optical Coherence Tomography Imaging Analysis

2020 ◽  
Vol 10 (1) ◽  
pp. 80
Author(s):  
Recha Blessing ◽  
Majid Ahoopai ◽  
Martin Geyer ◽  
Moritz Brandt ◽  
Andreas M. Zeiher ◽  
...  
Keyword(s):  
Optical Coherence Tomography ◽  
Chronic Total Occlusion ◽  
Quantitative Coronary Angiography ◽  
Dual Therapy ◽  
Coronary Stent ◽  
Neointima Formation ◽  
Optical Coherence ◽  
Total Occlusion ◽  
Angiographic Restenosis

We sought to determine the effects of the use of a Bioengineered Combo Dual-Therapy CD34 Antibody-Covered Sirolimus-Eluting Coronary Stent (Combo® DTS) in patients with chronic total occlusion (CTO) by evaluating clinical outcomes and by performing an optical coherence tomography (OCT) analysis. We retrospectively analyzed data from 39 patients who had successfully undergone OCT-guided revascularization of a CTO being treated with a Combo® DTS. Clinical assessment, angiography (with quantitative coronary angiography analysis) and OCT examination were performed at baseline and at follow-up. The median follow-up period was 189 days, ranging from 157 to 615 days. At follow-up, revascularization was required due to angiographic restenosis in 40% (14 of 35) of patients. OCT analysis detected neointima proliferation in 23 (76.6%) patients. Neointima formation was often associated with microvessels in 18 patients (60%). Neoatheroslcerosis was observed in 2 (6.6%) patients. Malapposition was found in 4 patients (13.3%), and stent fractures were found in 11 patients (36.6%). Rate of strut coverage was 96.3% at follow-up. In conclusion, the implantation of a Combo® DTS after successful CTO recanalization was associated with a restenosis rate of 40% despite good stent implantation at baseline, proven by OCT. Neointima formation was found as a main contributor to restenosis. Nevertheless, we observed a low rate of major cardiovascular events in our follow-up.

Optical coherence tomography follow-up of the subintimal tracking and re-entry technique for chronic total occlusion

2010 ◽  
Vol 6 (5) ◽  
pp. 662-663 ◽  
Author(s):  
Giampaolo Niccoli ◽  
Giuseppe Ferrante ◽  
Alfredo Galassi ◽  
Rocco Montone ◽  
Filippo Crea
Keyword(s):  
Optical Coherence Tomography ◽  
Chronic Total Occlusion ◽  
Optical Coherence ◽  
Total Occlusion

A honeycomb-like structure in chronic total occlusion demonstrated by frequency-domain optical coherence tomography

2015 ◽  
Vol 186 ◽  
pp. 239-240 ◽  
Author(s):  
Yusuke Fujino ◽  
Guilherme F. Attizzani ◽  
Satoko Tahara ◽  
Kensuke Takagi ◽  
Toru Naganuma ◽  
...  
Keyword(s):  
Optical Coherence Tomography ◽  
Frequency Domain ◽  
Chronic Total Occlusion ◽  
Optical Coherence ◽  
Total Occlusion

Neointimal Healing Evaluated by Optical Coherence Tomography after Drug-Eluting Absorbable Metal Scaffold Implantation in de novo Native Coronary Lesions: Rationale and Design of the Magmaris-OCT Study

Cardiology ◽  
2017 ◽  
Vol 137 (4) ◽  
pp. 225-230 ◽  
Author(s):  
Pasi Karjalainen ◽  
Tuomas Paana ◽  
Jussi Sia ◽  
Wail Nammas
Keyword(s):  
Optical Coherence Tomography ◽  
De Novo ◽  
Quantitative Coronary Angiography ◽  
Vessel Diameter ◽  
Target Lesion ◽  
Lesion Length ◽  
Optical Coherence ◽  
Flow Reserve ◽  
Coronary Lesions

Objectives: We sought to explore neointimal healing assessed by optical coherence tomography (OCT) following implantation of the Magmaris sirolimus-eluting absorbable metal scaffold. Methods: The Magmaris-OCT is a prospective, multicenter, single-arm observational clinical study, intended to enrol 60 consecutive patients with up to 2 de novo native coronary lesions, each located in different major epicardial vessels, with a reference vessel diameter of 2.5-3.5 mm, and a maximum lesion length of 20 mm. Patients will undergo Magmaris scaffold implantation in the target lesion, according to the standard practice. Clinical follow-up will take place at 30 days, and at 3, 6, 9, and 12 months. For invasive-imaging follow-up, patients will be classified into 3 groups: cohort A will be scheduled for follow-up at 3 months, cohort B at 6 months, and cohort C at 12 months. Invasive imaging will include quantitative coronary angiography, OCT evaluation, and coronary flow reserve measurement. The primary end point will be the percentage of uncovered scaffold struts assessed by OCT at the prespecified follow-up. Conclusions: This study will provide insight into the short- and mid-term healing properties following Magmaris scaffold implantation, with special emphasis on the neointimal coverage of scaffold struts.

Sign in / Sign up

Export Citation Format

Share Document